Published in Clin Cancer Res on December 18, 2015
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | NCT01353222
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | NCT01524991
Safety Study of MGA271 in Refractory Cancer | NCT01391143
MK-3475/BCG in High Risk Superficial Bladder Cancer (MARC) | NCT02324582
Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med (2016) 0.78
New Immunotherapy Strategies in Breast Cancer. Int J Environ Res Public Health (2017) 0.75
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer (2016) 0.75
Intravesical BCG induces CD4(+) T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunol Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 9.75
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
The future of immune checkpoint therapy. Science (2015) 5.59
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Neoantigens in cancer immunotherapy. Science (2015) 5.16
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
The present and future burden of urinary bladder cancer in the world. World J Urol (2009) 4.56
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
T cell exclusion, immune privilege, and the tumor microenvironment. Science (2015) 1.88
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother (2006) 1.81
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70
T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res (2008) 1.58
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol (2014) 1.48
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) (2012) 1.46
PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One (2015) 1.45
Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract (2002) 1.45
Science gone translational: the OX40 agonist story. Immunol Rev (2011) 1.39
Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res (2013) 1.32
Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol (1980) 1.29
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int (2013) 1.24
B7-H3-mediated tumor immunology: Friend or foe? Int J Cancer (2013) 1.23
Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol (2006) 1.18
Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol (2004) 1.15
CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol (2014) 1.10
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res (2012) 1.06
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol (2006) 1.06
Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol (2001) 1.05
Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol (1987) 1.04
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol (1987) 1.03
Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol (2013) 0.96
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res (2009) 0.94
Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab (2014) 0.93
The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol (2013) 0.90
Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv Urol (2012) 0.86